A trial update for linaclotide was recorded on May 6, 2026. The study, titled "Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis," is registered under identifier NCT07569419.
The trial is listed as an early phase 1 study. Its current status is recruiting. This designation indicates the study is in an early stage and is actively enrolling participants as of the date reported.
No results, efficacy data, or safety findings have been reported for this trial at this time. The listing reflects only the trial's design phase and recruitment status. Further updates would be needed to determine outcomes as the study progresses.
Linaclotide is an approved compound, though this particular trial explores its use in a different context, cystic fibrosis, rather than its approved indication. Readers interested in the study details can consult the official listing at ClinicalTrials.gov under the identifier provided.
For additional background on linaclotide, including its approved uses and general profile, readers can consult the compound overview.